RxDoctor Payments Data

Jessica Davis

Nurse Practitioner · Santa Barbara, CANPI 1528215076

Payments from drug & device makers

$4,598in general payments, 2019–2025

Across 83 payments — averaging $55.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$2K
  • E.r. Squibb & Sons, L.L.C.$600
  • Pfizer$581
  • Johnson & Johnson$212
  • AbbVie$210
  • AstraZeneca$201
  • plus $1K from 20 others

What the payments were for

  • Consulting fees$2,10046%
  • Speaking & faculty fees$54012%
  • Food & beverage$1,84040%
  • Education$1022%
  • Other$170%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,598 in reported general payments places this provider in the 90th percentile of 6,779 nurse practitioner providers in California.

See all nurse practitioner providers in California

Medicare billing

Part B allowed, 2024
$88,812
Medicare patients
380
Services billed
943

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IbrancePalbociclib14$220,001
EliquisApixaban54$39,635
XareltoRivaroxaban13$19,355
Fentanyl22$2,262
Imatinib Mesylate18$2,187
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen46$1,256
Oxycodone Hcl36$821
Acyclovir23$616
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen33$614
Dexamethasone18$488
Omeprazole45$478
Olanzapine22$471
Morphine Sulfate ErMorphine Sulfate16$468
Tamoxifen Citrate16$462
Gabapentin52$364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerIbrance, Eliquis$581$259,63668 claims
Johnson & JohnsonXarelto$212$19,35513 claims
Lilly USA, LLCOlanzapine$60$47122 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 6,779 nurse practitioner providers in California.

Other nurse practitioner in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →